Skip to main content
OpenTrials
Enrolling by Invitation

NCT Number: NCT07296549

Expert Consensus on the Clinical Management of Melasma: A Delphi Method Study

This study aims to gather expert opinions on the best ways to treat and manage melasma, a common skin condition characterized by dark patches on the face. Using a method called the Delphi Method, a group of dermatologists and other specialists will participate in several rounds of surveys to share their insights and reach a consensus on the most effective treatments and management strategies. The goal is to create a set of evidence-based guidelines that can help doctors provide more consistent, effective care for patients with melasma. The study will ensure that all experts' opinions are anonymous, and the results will be shared to improve treatment practices worldwide.

Enrolling by Invitation

Interested in participating?

Request Info

Key information

Age range

25 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

Venus Research Center

Cairo, Egypt

About this study

This study is designed to establish expert consensus on the management and treatment of melasma through a Delphi Method approach. The Delphi Method is a structured, iterative process where a panel of specialists-primarily dermatologists and other healthcare professionals experienced in treating melasma-will be asked to respond to a series of surveys. These surveys will allow experts to share their opinions on the most effective treatments, diagnostic criteria, and management strategies for melasma.

The study will be conducted in multiple rounds:

Round 1: Experts will provide open-ended feedback on their experiences and perspectives on melasma treatment.

Round 2: Based on the responses from Round 1, a refined set of questions will be circulated to clarify or expand on the issues raised.

Round 3: A final round will help refine and solidify the consensus on treatment approaches and care protocols.

The experts' feedback will be anonymized to ensure unbiased responses, and each round will be followed by analysis to identify areas of agreement and disagreement. The goal is to achieve a high level of consensus (usually around 70%) on key treatment recommendations and best practices for managing melasma.

This process will result in evidence-based guidelines for melasma treatment that healthcare providers can use to standardize care and improve patient outcomes. These guidelines will help address the variability in treatment practices and ensure that patients receive the most effective and up-to-date care based on expert consensus.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Board-certified or equivalent dermatologist,
  • Minimum of 5 years of post-certification clinical experience in the management of MELASMA,
  • Willingness to participate in all Delphi rounds.

Exclusion criteria

  • Inability or unwillingness to complete Delphi rounds.
  • Lack of clinical experience with MELASMA
  • Industry representatives without direct clinical practice

Treatment and study plan

Primary outcomes

  1. Consensus on Diagnostic & therapeutic Criteria for Melasma

    Time frame: 6-12 weeks

    Establishment of expert consensus on core domains of melasma diagnosis and management measured by the proportion of statements reaching predefined consensus agreement after completion of delphi rounds

Sponsors and collaborators

Lead sponsor

Venus Research Center

Other

Registry information

Important dates

Study start
2026
Primary completion
2026
Study completion
2026
First posted
Dec 22, 2025
Registry last updated
Dec 29, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.